SAN DIEGO, May 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today that the Company will be added to the NASDAQ Biotechnology Index® (NBI). The semi-annual re-ranking of the index will become effective prior to market opening on Monday, May 21, 2012.
